SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

VX-407

VRTX·VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2a
Time to market
At least 3-5 years away, assuming positive Phase 2a results (primary completion July 2027) followed by successful pivotal trials and regulatory review.
Why 4/10
VX-407 has no FDA action or pivotal readout date within the next 12 months. The AGLOW Phase 2a proof-of-concept study (NCT07161037) is active but not recruiting, with estimated primary completion in July 2027 and study completion in December 2027. Since the next hard, dated catalyst is more than 6 months out and VX-407 is a small component of Vertex's diverse pipeline, the impact score is 4.
Actionable Insight NEUTRAL

The next hard catalyst for VX-407 is the AGLOW Phase 2a primary completion, estimated for July 2027. Positive proof-of-concept data on height-adjusted total kidney volume (htTKV) would establish VX-407 as a viable precision-medicine approach in ADPKD, while negative or null results would likely end the program. Investors should watch for interim data updates and enrollment/regulatory milestones in the coming quarters, but the far more impactful near-term catalyst for VRTX stock is the November 30, 2026 PDUFA date for povetacicept in IgA nephropathy.

Price Chart

Loading chart...

Executive Summary

VX-407 is Vertex Pharmaceuticals' first-in-class small molecule corrector for autosomal dominant polycystic kidney disease (ADPKD), targeting patients with specific PKD1 gene variants (approximately 10% of the ~250,000 ADPKD population). The FDA cleared the IND in March 2024. A Phase 1 safety study in healthy volunteers (NCT06345755) has been completed, and the Phase 2a proof-of-concept AGLOW study (NCT07161037) began in November 2025, has fully enrolled 26 patients, and is active but no longer recruiting. Primary completion is estimated for July 2027. Vertex also initiated two additional Phase 1 studies in 2026: a drug-drug interaction study with oral contraceptives and an ADME study. VX-407 represents Vertex's application of its protein-corrector platform to kidney disease, but at a very early stage it remains a small part of Vertex's pipeline, which is dominated by the cystic fibrosis franchise (Q3 2026 revenue $3.44 billion, +12% YoY) and more advanced kidney programs (povetacicept for IgAN with a November 30, 2026 PDUFA date, and inaxaplin for APOL1-mediated kidney disease in Phase 2b/3).

How It Works

VX-407 is a small molecule designed to fix a misfolded protein called polycystin-1 (PC1), which is defective in certain patients with autosomal dominant polycystic kidney disease (ADPKD). By correcting the folding of PC1, the drug aims to restore the protein's normal function, stop the growth of kidney cysts, slow kidney enlargement, and prevent progression to kidney failure. This mechanism is analogous to Vertex's CFTR correctors for cystic fibrosis, where small molecules repair misfolded proteins.

Trial Status

Phase 1 healthy-volunteer study (NCT06345755) completed. Phase 2a AGLOW study (NCT07161037) is active but not recruiting with 26 patients enrolled across 43 sites in 8 countries, started November 2025, estimated primary completion July 2027, estimated study completion December 2027. Additional Phase 1 studies ongoing: drug-drug interaction with oral contraceptives (started Sep 2026) and 14C-ADME study.

The Two-Sided Case

▲ Bull Case5
VX-407 is a first-in-class small molecule corrector designed to address the underlying cause of ADPKD by correcting defective PC1 folding, a novel mechanism compared to the only approved therapy (tolvaptan).
Vertex has a strong track record of successfully developing small molecule correctors, as demonstrated in cystic fibrosis, bolstering confidence in the platform approach.
If successful, VX-407 would be the first targeted therapy for PKD1-variant ADPKD, addressing a high unmet need in a life-shortening genetic kidney disease with only one approved drug.
Vertex's financial strength (Q3 2026 revenue of $3.44 billion, up 12% YoY) means the company can fully fund development without capital markets risk.
Investor interest in Vertex's kidney pipeline is growing following positive inaxaplin Phase 2b data in September 2026.
▼ Bear Case5
VX-407 targets only ~10% of the ADPKD population (~25,000 patients), limiting its peak revenue potential even if approved.
The AGLOW Phase 2a study is single-arm and open-label with only 26 patients, providing a limited dataset for proof-of-concept; a failed readout would halt the program.
Vertex already has a deep pipeline (CF franchise, povetacicept, inaxaplin, diabetes, pain), so VX-407 is a small component of the overall valuation; even a positive readout may not move the stock meaningfully.
Tolvaptan is the only approved ADPKD therapy and has an established market position, creating a high bar for a new entrant.
Phase 2a primary completion is estimated for July 2027, meaning no binary catalyst for this drug within the next 6 months.

Upcoming Catalysts

  • AGLOW Phase 2a primary completion estimated July 2027 (htTKV efficacy data)
  • Potential interim analysis or data updates from AGLOW in 2026-2027
  • Completion of Phase 1 DDI study with oral contraceptives (NCT07792408)
  • Completion of Phase 1 ADME study with 14C-VX-407 (NCT07868926)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report

Sources · 10

Hover a chip for the title
1 news.vrtx.com2 news.vrtx.com3 clinicaltrials.gov4 clinicaltrials.gov5 pkdcuretracker.com6 vrtx.com7 pharmaceutical-technology.com8 gurufocus.com9 benzinga.com10 synapse.patsnap.com